DotLab is a women's healthcare technology company focused on revolutionizing the diagnosis of endometriosis through its innovative product, DotEndo. This non-invasive blood test identifies active endometriosis by measuring specific biomarkers in the blood, which serve as a unique signature for the disease. DotEndo addresses a significant diagnostic gap, as the average time to receive an endometriosis diagnosis can take up to eleven years. By utilizing biostatistics to analyze these biomarkers, DotEndo provides actionable results that can expedite the diagnostic process, allowing for earlier treatment and potentially preventing disease progression.

The scientific foundation of DotEndo is built on over a decade of peer-reviewed research that links microRNA biomarkers to endometriosis and infertility. The test offers a definitive positive or negative result rather than a risk profile, enhancing the clarity of diagnosis for patients. DotLab's commitment to advancing women's health is further exemplified by ongoing clinical studies, such as the EMPOWER Study, which aims to gather more data on the effectiveness of DotEndo in diagnosing endometriosis in a diverse population of women. Through these efforts, DotLab is dedicated to improving health outcomes for those affected by this prevalent condition.

United States

DotLab measuresdisease-specific biomarkers and appliesadvanced biostatisticsfor non-invasiveendometriosis​ testing. ​​​​​​

DotLab

Company Details